Pfizer Inc. is poised to highlight key advances from its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, which runs from October 17 to 21 in Berlin. With over 45 abstracts, including 11 oral and mini oral...
Illumina Inc. has announced global partnerships with top pharmaceutical companies for companion diagnostics (CDx) on Illumina’s TruSight Oncology (TSO) Comprehensive genomic profiling test. The collaboration focuses on KRAS alterations...
AbbVie, a global biopharmaceutical leader, hosted the National Conclave on World Retina Day at the India Habitat Centre, Delhi, which focused on Diabetic Macular Edema
Poly Medicure Ltd., a prominent medical device manufacturing company in India, has made public the signing of a conclusive agreement for the purchase of Medistream SA, the parent of Citieffe SRL
Glenmark Specialty S.A. (GSSA), a fully owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), announced that it and Hengrui Pharma have signed an exclusive license and collaboration agreement for the next-generation HER2-targeting antibody
The US FDA has granted fast track designation to Sanofi’s SAR446268, an experimental gene therapy for myotonic dystrophy type 1 (DM1). This rare progressive neuromuscular disease affects about 1 in 2300 people globally, and has no approved...
.jpeg){kind=spacer}
Novo Nordisk's declaration to put an end to its Penfill and FlexPen products in India by December 2023, Indian pharmaceutical companies like Eris Lifesciences, Wockhardt, and Lupin, are getting ready to capitalize the local human insulin
QIAGEN today announced the conclusion of the gastrointestinal (GI) consensus meeting, which convened leading gastroenterology experts from across Asia-Pacific
The first ‘Manipal cGMP Forum: National Conference on cGMP & Compliance’, will be a day dealing with the theme “cGMP for Sustainable Quality”, will take place on October 10, 2025 at the Dr TMA Pai Auditorium, MAHE, Manipal.
New data from the HS-OBTAIN phase 2a study (NCT05849922) that has been released today at the EADV 2025 Congress in Paris shows that the investigational therapy brivekimig has most significantly improved the region of skin disease in patients with...
.jpg)
, CDSCO.jpg)